Basel, April 4, 2019 - Novartis announced today that there is a legal dispute with Amgen regarding the collaboration agreements in the field of migraine. On April 2, 2019, Amgen issued a notice of termination of its migraine collaboration agreements with Novartis based on an alleged material breach of the collaboration agreements. Novartis disputes the notice vigorously. In order to prevent an unjustifiable attempt by Amgen to end the collaboration, Novartis has filed a lawsuit asking the court to confirm that Amgen has no right to terminate the agreements. The agreements will remain in force unless and until a final and binding court decision is pronounced that terminates the agreements.

Novartis has brought a unique and established neuroscience footprint and expertise to the collaboration and has also made significant financial investments in the development and worldwide commercialization of Aimovig® (erenumab), a preventive treatment for migraine. Novartis considers the notice of termination unjustified and without legal merit. The dispute does not affect the Novartis vision and commitment to help people suffering from migraine worldwide.

Disclaimer
This Statement contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as "in order to prevent," "asking," "will," "unless and until," "vision," "commitment," or similar etc. etc..

Novartis is on Twitter. Sign up to follow @Novartis at http://twitter.com/novartis
For Novartis multimedia content, please visit www.novartis.com/news/media-library
For questions about the site or required registration, please contact media.relations@novartis.com

# # #